🔗 Share this article

Given that America continues making historic changes to its vaccination recommendations, an unexpected name has emerged somewhat surprisingly: Tracy Beth Høeg, a Danish American sports medicine doctor and epidemiologist who first made her name by expressing skepticism about Covid vaccines during the pandemic and has zeroed in on potential fatalities following COVID-19 immunization in her recent position at the FDA.

Scheduled Shifts to Pediatric Vaccine Schedule

Public health authorities had intended to announce radical revisions to the pediatric vaccine schedule earlier this month, synchronizing the US with the Danish national calendar, sources say – a major change that would place the US at odds with much of the global community with little proof for benefit. This reveal has been delayed until the coming year.

Rather than the director of the vaccine center, Dr. Høeg is scheduled to speak at the event. She was recently named acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to lead the division this year.

Consolidating Power at the FDA

The acting appointment might represent a closer partnership between the pharmaceutical and biologics branches as Høeg and Prasad solidify control at the agency – and it points to a greater focus upon dismantling long-standing vaccines at the FDA.

The new acting director has repeatedly called for halting certain pediatric immunization guidelines in the US to become more like Denmark's approach, a society with nationalized medicine and a number of inhabitants roughly the size of Wisconsin’s.

So far comments, she has kept her attention on vaccination policy – traditionally the domain of Dr. Prasad, head of the FDA’s vaccine center – rather than drug regulation.

Concerns Over Qualifications

Dr. Høeg has little discernible background in pharmaceutical research, regulation or management, which has been customary for former leaders of the biologics center. She has served at the FDA as a senior adviser to the commissioner and the vaccine center since March.

“She doesn’t seem to have the necessary background” for leading the CDER, remarked a neurologist and psychiatrist. “She has not conducted a randomized controlled trial. She has no expertise in running a sizeable institution. She is not an expert in pharmaceutical oversight.”

Past commissioners of CBER would “grasp regulatory frameworks and the research of medication creation”, said Janet Woodcock. “Frankly, she doesn’t have the sort of resume that former directors who headed the center have had.”

The drug center has an immense range of responsibilities at the FDA, she emphasized.

“The public just focuses on the new drug program, but the off-patent medication office approves numerous generic medications. There is also a biosimilars division, OTC medication office and more, and every single one have to be looked after,” Dr. Woodcock noted. “The area you neglect, that’s the thing that I always told people is going to cause problems.”

There is also, a significant administrative aspect to the role, which oversees more than 5,000 staff members. “It’s a huge administrative position, if you perform it correctly,” Woodcock added.

Response and Controversial Programs

Regarding concerns about Dr. Høeg's credentials and whether this assignment signifies more teamwork among FDA leaders on immunizations, a spokesperson said that the “concerns are based on inaccurate presumptions”.

“This background aligns with the duties of her role,” the spokesperson stated, citing the time Dr. Høeg spent advising the FDA commissioner on “pharmaceutical safety and approval science, including predictive safety algorithms and immunization monitoring”.

As acting director, Høeg takes over the agency head's recently launched expedited review system, a contentious expedited therapy clearance system that apparently concerned her preceding directors. “How are these medications being picked for this expedited pathway? Who makes the choices?” Howard asked. “There is a lot of confidentiality occurring at the agency right now.”

In general, he remarked, “the Food and Drug Administration looks to be trending towards more relaxed rules of pharmaceuticals, except for vaccines.”

Public Past Work on Vaccines

Concerning vaccines, Høeg has a more established, if problematic, past, Howard observe. She published a analysis using non-validated volunteer-provided data to estimate the rate of myocarditis after Covid immunization. She counseled the state of Florida top health official Joseph Ladapo, who allegedly have altered data to suggest Covid vaccinations are more dangerous than they are.

Part of her “wish list” for the incoming federal leadership featured revising rules for novel immunizations and ending “optional” vaccines, she stated post-election on a podcast. At the agency, Høeg has reportedly suggested barring young men from receiving COVID-19 vaccines.

“She’s an all-around dogmatist who starts off with her beliefs and works backwards to accommodate the evidence in a highly misleading, dishonest fashion,” Dr. Howard argued.

Taking Control and a “Campaign of Retribution”

Høeg aligned with other contrarians, {like|